To the full analysis
Shenzhen New Industries Biomedical Engineering stock: growth
300832.SZShenzhen New Industries Biomedical Engineering reported $686.35M in revenue for fiscal 2025, up 0.9% on the prior year, up 15.8% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
24.8%
per year from 2012 to 2025, per share 23.4%
Earnings (Annual rate)
26.6%
per year from 2012 to 2025, per share 25.3%
Free cash flow (Annual rate)
29.4%
per year from 2012 to 2025, per share 28%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2012 | |
|---|---|---|---|
| Revenue | 15.8% | 20.1% | 24.8% |
| Revenue per share | 15.7% | 18.6% | 23.4% |
| Earnings | 11.5% | 20.6% | 26.6% |
| Earnings per share | 10.5% | 19.1% | 25.3% |
| Free cash flow | 11.5% | 20.9% | 29.4% |
| Free cash flow per share | 11.4% | 19.4% | 28.0% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2012 | $38.7M | $11.27M | $6.52M |
| 2013 | $56.7M | $21.19M | −$692.66K |
| 2014 | $81.77M | $37.92M | $18.64M |
| 2015 | $109.73M | $37.36M | $27.96M |
| 2016 | $138.34M | $67.74M | $64.6M |
| 2017 | $171.04M | $80.71M | $52.22M |
| 2018 | $207.49M | $104.07M | $62.55M |
| 2019 | $252.18M | $115.86M | $75.67M |
| 2020 | $329.17M | $140.84M | $108.25M |
| 2021 | $381.72M | $146.02M | $64.53M |
| 2022 | $456.93M | $199.14M | $83.86M |
| 2023 | $589.31M | $247.99M | $164.38M |
| 2024 | $680.15M | $274.2M | $137.55M |
| 2025 | $686.35M | $242.98M | $186.22M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = CN¥6.6683)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 3 Jul 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.